Bone Disease Associated with Diabetes Mellitus: Particularly Focusing on Its Contribution to the Development of Atherosclerosis

  • Masaaki InabaEmail author


Bone abnormality associated with diabetes mellitus (DM) is characterized by its low bone turnover status (Krakauer et al. Diabetes 44(7):775–782, 1995). Suppression of bone turnover occurs in DM by several mechanisms, such as (i) the impaired secretion of parathyroid hormone (Inaba et al. Am J Kidney Dis 39(6):1261–1269, 2002; Inaba et al. Am J Kidney Dis 38(4 Suppl 1):S139–S142, 2001) and (ii) osteocyte/osteoblast deficit, which are caused by the sustained high glucose condition (Inaba et al. Osteoporos Int 7 (suppl 3): S209–S212, 1997) or insulin/insulin-like growth factor-1 deficiency (Wettenhall et al. Diabetes 18:280–284, 1969). Therefore, DM is recently recognized as the disease which causes often adynamic bone disease (ABD), which cause higher fracture rate in spite of no apparent reduction in bone mass (Vestergaard Osteoporos Int 18: 427–44, 2007). The decrease in the number and activity of osteeoblasts/osteocytes impaired the secretion of fibroblast growth factor (FGF)-23 from the cells (Yoda et al. J Clin Endocrinol Metab 97(11):E2036–E2043, 2012), resulting in the development of hyperphosphatemia due to phosphate overloading. Furthermore, ABD is a major risk factor for vascular calcification by diminishing the capacity of bone to adsorb surplus calcium and phosphate in circulation (London et al. J Am Soc Nephrol 15(7):1943–1951, 2004).

Therefore, it is recognized that the suppression of bone turnover with the deficit of osteocyte/osteoblast might enhance atherosclerotic change by disturbing phosphate/calcium metabolism in DM patients.


Diabetes Bone Atherosclerosis Adynamic bone disease (ABD) FGF-23 


Conflict of Interest

Masaaki Inaba declares that he has no conflict of interest.


  1. 1.
    Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM (1995) Bone loss and bone turnover in diabetes. Diabetes 44(7):775–782CrossRefPubMedGoogle Scholar
  2. 2.
    Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, Shoji T, Ishimura E, Ohta T, Nakatani T, Kim M, Nishizawa Y (2002) Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39(6):1261–1269CrossRefPubMedGoogle Scholar
  3. 3.
    Inaba M, Okuno S, Nagasue K, Otoshi T, Kurioka Y, Maekawa K, Kumeda Y, Imanishi Y, Ishimura E, Ohta T, Morii H, Kim M, Nishizawa Y (2001) Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am J Kidney Dis 38(4 Suppl 1):S139–S142CrossRefPubMedGoogle Scholar
  4. 4.
    Inaba M, Nishizawa Y, Shioi A, Morii H (1997) Importance of sustained high glucose condition in the development of diabetic osteopenia: possible involvement of the polyol pathway. Osteoporos Int 7(suppl 3):S209–S212CrossRefPubMedGoogle Scholar
  5. 5.
    Wettenhall REH, Schwqarz PL, Bornstein J (1969) Actions of insulin and growth hormone on collagen and chondroitin sulfate synthesis in bone organ cultures. Diabetes 18:280–284CrossRefPubMedGoogle Scholar
  6. 6.
    Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMedGoogle Scholar
  7. 7.
    Yoda K, Imanishi Y, Yoda M, Mishima T, Ichii M, Yamada S, Mori K, Emoto M, Inaba M (2012) Impaired response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab 97(11):E2036–E2043CrossRefPubMedGoogle Scholar
  8. 8.
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15(7):1943–1951CrossRefPubMedGoogle Scholar
  9. 9.
    Leman J Jr, Lennon EJ, Piering WR, Prien EL Jr, Ricinati ES (1970) Evidence that glucose ingestion inhibits net renal tubular reabsorption of calcium and magnesium in man. J Lab Clin Med 75:578–585Google Scholar
  10. 10.
    Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22:17–23CrossRefPubMedGoogle Scholar
  11. 11.
    Rico H, Hernandez ER, Cabranes JA, Gomez-Castresana F (1989) Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics. Calcif Tissue Int 45:71–73CrossRefPubMedGoogle Scholar
  12. 12.
    Yamada S, Inaba M, Okada S, Imanishi Y, Mori K, Emoto M, Ishimura E, Nishizawa Y (2010) Association of glycated albumin, but not glycated hemoglobin, with calcaneus quantitative ultrasound in male hemodialysis patients with type 2 diabetes mellitus. Metabolism 59(3):390–394CrossRefPubMedGoogle Scholar
  13. 13.
    Kurajoh M, Inaba M, Okuno S, Nagayama H, Yamada S, Imanishi Y, Ishimura E, Shoji S, Yamakawa T, Nishizawa Y (2011) Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. Osteoporos Int 22(3):923–930CrossRefPubMedGoogle Scholar
  14. 14.
    Inaba M, Okuno S, Imanishi Y, Ishimura E, Yamakawa T, Shoji S (2013) Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients. Osteoporos Int 24(11):2863–2870, Kobayashi I, Life SciCrossRefPubMedGoogle Scholar
  15. 15.
    Kobayashi I, Shidara K, Okuno S, Yamada S, Imanishi Y, Mori K, Ishimura E, Shoji S, Yamakawa T, Inaba M (2012) Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. Life Sci 90(5–6):212–218CrossRefPubMedGoogle Scholar
  16. 16.
    Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 84(3):180–185CrossRefPubMedGoogle Scholar
  17. 17.
    Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M (2008) Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74(10):1270–1277CrossRefPubMedGoogle Scholar
  18. 18.
    Okamoto K, Inaba M, Furumitsu Y, Ban A, Mori N, Yukioka K, Imanishi Y, Nishizawa Y (2010) Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. Life Sci 87(23–26):686–691, Bis &AMICrossRefPubMedGoogle Scholar
  19. 19.
    Kang JH, Keller JJ, Lin HC (2013) Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 24(1):271–277CrossRefPubMedGoogle Scholar
  20. 20.
    Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87(7):E10–E17CrossRefPubMedGoogle Scholar
  21. 21.
    Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G, REIN Study Group (2011) Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 22(10):1923–1930CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Inaba M, Terada M, Koyama H, Yoshida O, Ishimura E, Kawagishi T, Okuno Y, Nishizawa Y, Otani S, Morii H (1995) Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 10(7):1050–1056CrossRefPubMedGoogle Scholar
  23. 23.
    Yoshida O, Inaba M, Terada M, Shioi A, Nishizawa Y, Otani S, Morii H (1995) Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 21(1–3):201–204PubMedGoogle Scholar
  24. 24.
    Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrol (Carlton) 16(3):290–298CrossRefGoogle Scholar
  25. 25.
    London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC (2008) Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 19(9):1827–1835CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Inaba M, Okuno S, Nagayama H, Yamada S, Ishimura E, Imanishi Y, Shoji S (2015) Restoration of parathyroid function after change of phosphate binder form calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone. J Ren Nutr 25(2):242–246Google Scholar
  27. 27.
    Yajima A, Inaba M, Tominaga Y, Tanaka M, Otsubo S, Nitta K, Ito A, Satoh S (2013) Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease. Ther Apher Dial 17(Suppl 1):41–48CrossRefPubMedGoogle Scholar
  28. 28.
    Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y (2008) Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf) 69(2):189–196CrossRefGoogle Scholar
  29. 29.
    Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y (2002) Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients – importance of glycaemic control. Diabetologia 45(10):1446–1448CrossRefPubMedGoogle Scholar
  30. 30.
    Taniwaki H, Ishimura E, Tabata T, Tsujimoto Y, Shioi A, Shoji T, Inaba M, Inoue T, Nishizawa Y (2005) Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 20:2472–2478CrossRefPubMedGoogle Scholar
  31. 31.
    Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K, Yamakawa T, Imanishi Y, Inaba M, Nishizawa Y (2007) Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49(3):417–425CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Department of Metabolism, Endocrinology and Molecular MedicineOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations